No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Antibody Structure

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • HTML
    85.77 Kb
  • XML
    74.73 Kb
  • PDF
    524.26 Kb
  • Authors: Robyn L. Stanfield1, Ian A. Wilson2
  • Editors: James E. Crowe Jr.4, Diana Boraschi5, Rino Rappuoli6
    Affiliations: 1: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037; 2: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037; 3: Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037; 4: Vanderbilt University School of Medicine, Nashville, TN; 5: National Research Council, Pisa, Italy; 6: Novartis Vaccines, Siena, Italy
  • Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013
  • Received 28 May 2013 Accepted 28 October 2013 Published 21 March 2014
  • Address correspondence to: Robyn L. Stanfield, [email protected]
image of Antibody Structure
    Preview this microbiology spectrum article:
    Zoom in

    Antibody Structure, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/2/2/AID-0012-2013-1.gif /docserver/preview/fulltext/microbiolspec/2/2/AID-0012-2013-2.gif
  • Abstract:

    A brief outline of antibody structure is followed by highlights from several recently determined crystal structures of human, antiviral Fabs. These Fabs all have novel structural features that allow them to potently and broadly neutralize their targets.

  • Citation: Stanfield R, Wilson I. 2014. Antibody Structure. Microbiol Spectrum 2(2):AID-0012-2013. doi:10.1128/microbiolspec.AID-0012-2013.


1. Arnaout R, Lee W, Cahill P, Honan T, Sparrow T, Weiand M, Nusbaum C, Rajewsky K, Koralov SB. 2011. High-resolution description of antibody heavy-chain repertoires in humans. PLoS One 6:e22365. [PubMed][CrossRef]
2. Palm W. 1974. The physico-chemical characterization and crystallization of immunoglobulins and their fragmentation products: a contribution to the elucidation of the three-dimensional structure of antibodies. II. Human immunoglobulin Kol: a myeloma protein of the class IgG, gamma2 kappa2. Hoppe Seylers Z Physiol Chem 355:877–880. [PubMed]
3. Amzel LM, Poljak RJ, Saul F, Varga JM, Richards FF. 1974. The three dimensional structure of a combining region-ligand complex of immunoglobulin NEW at 3.5-Å resolution. Proc Natl Acad Sci USA 71:1427–1430. [PubMed]
4. Berman H, Henrick K, Nakamura H. 2003. Announcing the worldwide Protein Data Bank. Nat Struct Biol 10:980. [PubMed][CrossRef]
5. Chothia C, Lesk AM. 1987. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196:901–917. [PubMed]
6. Al-Lazikani B, Lesk AM, Chothia C. 1997. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273:927–948. [PubMed][CrossRef]
7. Martin AC, Thornton JM. 1996. Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. J Mol Biol 263:800–815. [PubMed][CrossRef]
8. North B, Lehmann A, Dunbrack RL Jr. 2011. A new clustering of antibody CDR loop conformations. J Mol Biol 406:228–256. [PubMed][CrossRef]
9. Wilson IA, Stanfield RL. 1994. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol 4:857–867. [PubMed]
10. Wilson IA, Stanfield RL. 1993. Antibody-antigen interactions. Curr Opin Struct Biol 3:113–118.
11. MacCallum RM, Martin AC, Thornton JM. 1996. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262:732–745. [PubMed][CrossRef]
12. Stanfield RL, Takimoto-Kamimura M, Rini JM, Profy AT, Wilson IA. 1993. Major antigen-induced domain rearrangements in an antibody. Structure 1:83–93. [PubMed]
13. Stanfield RL, Wilson IA. 1994. Antigen-induced conformational changes in antibodies: a problem for structural prediction and design. Trends Biotechnol 12:275–279. [PubMed][CrossRef]
14. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. 1991. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 88:4363–4366. [PubMed]
15. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. 1991. Making antibody fragments using phage display libraries. Nature 352:624–628. [PubMed][CrossRef]
16. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR, Wyatt RT, Wardemann H, Nussenzweig MC. 2009. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 343:65–67. [PubMed][CrossRef]
17. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289. [PubMed][CrossRef]
18. Zhang C. 2012. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol Biol 901:117–135. [PubMed][CrossRef]
19. Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler JA, Schroeder HW Jr, Kirkham PM. 2003. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 334:733–749. [PubMed]
20. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA 107:11483–11488. [PubMed][CrossRef]
21. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84:8098–8110. [PubMed][CrossRef]
22. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336–343. [PubMed][CrossRef]
23. Collis AV, Brouwer AP, Martin AC. 2003. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 325:337–354. [PubMed]
24. Briney BS, Willis JR, Crowe JE Jr. 2012. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 7:e36750. [PubMed][CrossRef]
25. Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD. 2011. Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol 85:2524–2535. [PubMed][CrossRef]
26. Spurrier B, Sampson JM, Totrov M, Li H, O'Neal T, Williams C, Robinson J, Gorny MK, Zolla-Pazner S, Kong XP. 2011. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120. Structure 19:691–699. [PubMed][CrossRef]
27. Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huang CC, Grundner C, Dorfman T, Zwick MB, Wang L, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114:161–170. [PubMed]
28. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317:1930–1934. [PubMed][CrossRef]
29. Stanfield RL, Dooley H, Flajnik MF, Wilson IA. 2004. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 305:1770–1773. [PubMed][CrossRef]
30. Nuttall SD. 2012. Overview and discovery of IgNARs and generation of VNARs. Methods Mol Biol 911:27–36. [PubMed][CrossRef]
31. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. 1994. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 7:1129–1135. [PubMed]
32. Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegoni M. 1996. The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3:752–757. [PubMed]
33. Muyldermans S, Cambillau C, Wyns L. 2001. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 26:230–235. [PubMed]
34. Stanfield RL, Dooley H, Verdino P, Flajnik MF, Wilson IA. 2007. Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. J Mol Biol 367:358–372. [PubMed][CrossRef]
35. Fanning SW, Horn JR. 2011. An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop. Protein Sci 20:1196–1207. [PubMed][CrossRef]
36. Vanlandschoot P, Stortelers C, Beirnaert E, Ibanez LI, Schepens B, Depla E, Saelens X. 2011. Nanobodies(R): new ammunition to battle viruses. Antiviral Res 92:389–407. [PubMed][CrossRef]
37. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O’Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA. 2012. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489:526–532. [PubMed][CrossRef]
38. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246–251. [PubMed][CrossRef]
39. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265–273. [PubMed][CrossRef]
40. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA. 2008. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105:5986–5991. [PubMed][CrossRef]
41. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942. [PubMed][CrossRef]
42. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang MY, Dimitrov DS, Hendrickson WA, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong PD. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci USA 101:2706–2711. [PubMed][CrossRef]
43. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G, Bianchi E, Miller MD, Pessi A, Carfi A. 2006. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13:740–747. [PubMed][CrossRef]
44. Thomson CA, Bryson S, McLean GR, Creagh AL, Pai EF, Schrader JW. 2008. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J 27:2592–2602. [PubMed][CrossRef]
45. Lee CV, Hymowitz SG, Wallweber HJ, Gordon NC, Billeci KL, Tsai SP, Compaan DM, Yin J, Gong Q, Kelley RF, DeForge LE, Martin F, Starovasnik MA, Fuh G. 2006. Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 108:3103–3111. [PubMed][CrossRef]
46. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097–1103. [PubMed][CrossRef]
47. Ghiara JB, Stura EA, Stanfield RL, Profy AT, Wilson IA. 1994. Crystal structure of the principal neutralization site of HIV-1. Science 264:82–85. [PubMed]
48. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711. [PubMed][CrossRef]
49. Huber M, Le KM, Doores KJ, Fulton Z, Stanfield RL, Wilson IA, Burton DR. 2010. Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol 84:10700–10707. [PubMed][CrossRef]
50. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065–2071. [PubMed][CrossRef]
51. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 102:13372–13377. [PubMed][CrossRef]
52. Krause JC, Ekiert DC, Tumpey TM, Smith PB, Wilson IA, Crowe JE Jr. 2011. An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody. MBio 2:e00345–e00310. [PubMed][CrossRef]
53. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin O, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337:1343–1348. [PubMed][CrossRef]
54. Saini SS, Allore B, Jacobs RM, Kaushik A. 1999. Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Eur J Immunol 29:2420–2426. [PubMed][CrossRef]
55. Wang F, Ekiert DC, Ahmad I, Yu W, Zhang Y, Bazirgan O, Torkamani A, Raudsepp T, Mwangi W, Criscitiello MF, Wilson IA, Schultz PG, Smider VV. 2013. Reshaping antibody diversity. Cell 153:1379–1393. [PubMed][CrossRef]
56. Kraulis PJ. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24:946–950.
57. Merritt EA, Bacon DJ. 1997. Raster3D: photorealistic molecular graphics. Methods Enzymol 277:505–524. [PubMed]

Article metrics loading...



A brief outline of antibody structure is followed by highlights from several recently determined crystal structures of human, antiviral Fabs. These Fabs all have novel structural features that allow them to potently and broadly neutralize their targets.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...



Image of FIGURE 1

Click to view


Extremely long CDR H3 loops in human anti-HIV-1 antibodies targeting the V1/V2 region of gp120 in the Env trimer. Fab PG16 (left, PDB 3mug) has a large (28/30 residue), structured “hammerhead” CDR H3 (red) with posttranslational modifications of one sulfated tyrosine and one N-linked glycan. PG9 (middle, PDB 3u4e) in complex with the V1/V2 domain (yellow) from HIV-1 gp120 (CAP45 isolate) uses its large CDR H3 to bisect two glycans (shown in yellow ball-and-stick representation) and form a parallel β-sheet interaction with one strand from V1/V2. PG9 has two sulfated tyrosine residues at its tip. Fab PGT145 (right, PDB 3u1s) has the longest CDR H3 (31/33 residues) yet seen in human antibodies. This CDR also has two sulfated tyrosine residues at its tip. For the Cα trace of both Fabs, the CDR loops are colored orange (L1), magenta (L2), green (L3), blue (H1), pink (H2), and red (H3), with light chains in light gray and heavy chains in dark gray. All figures were made with MOLSCRIPT ( 56 ) and rendered with Raster3D ( 57 ).

Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2

Click to view


Broadly neutralizing Fab CR6261 (left) uses only its heavy chain (dark gray, with blue, pink, and red CDR loops) to recognize the stem region of a hemagglutinin trimer. Fab C05 (right) binds to a conserved region near the receptor binding site, using mainly its large CDR H3 (red), with minor contact from CDR H1 (blue).

Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3

Click to view


Self-carbohydrate recognition by HIV-1 antibodies. (Left) Dimeric, domain-swapped 2G12 binds the D1 arms of GlcNAcMan (yellow) via two closely spaced primary combining sites. A third potential binding site, located between the closely spaced V and V′ domains, binds symmetry-related sugars (orange). (Middle and right) PGT128 also binds to two sugar moieties and inserts its CDR H3 (red) and long H2 (magenta) between two high-mannose sugars to contact the protein surface. The Fab-antigen complex is shown from two different sides to illustrate the interaction. 2G12, PGT128, and PG9 ( Fig. 1 ) bind two high-mannose sugars, either with two separate binding sites, as in 2G12, or by wedging long CDR loops between two carbohydrates, as in PGT128 and PG9 recognition.

Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4

Click to view


Diversity in the shape of antibody combining sites. Fab domain swapping and extremely long CDR H3 loops result in unusually shaped paratopes. (Top) Fv molecular surfaces are shown in gray, with paratopes (if known) colored in magenta and antigens shown in yellow. Classic antibody binding sites are usually pockets for small haptens (DB3, progesterone), grooves for peptides (B13I2, myohemerythrin peptide; 17/9, influenza peptide), or flat, undulating surfaces for proteins (HyHEL-10, lysozyme; HyHEL-5, lysozyme). (Bottom) In contrast, domain-swapped 2G12 has created a paratope consisting of 4 different binding pockets, and PGT128 and PG9 have protruding, convex paratopes that can be inserted between two large carbohydrate moieties. A structure of PGT145 with its antigen has not yet been determined, but its very long CDR H3 can be clearly visualized.

Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5

Click to view


Unusual insertions in CDRs H1 and H2 from Fabs C05 (red), 2D1 (yellow), and PGT128 (blue). (Left) In these H1 CDRs, the colored areas cover residues H26 to H35b. C05 has an unusually long 5-residue insertion in H1, while PGT128 and 2D1 have more common 2-residue insertions in H1. The 2D1 H1 CDR has shifted away its canonical conformation due to a clash with its long H2 loop. (Right) H2 CDRs from the same Fabs, with the same coloring from positions H51 to H57. C05 has a normal H2 CDR with a 1-residue insertion after residue 52. PGT128 has a very rare 6-residue insertion in this CDR, which is reflected in its unusually long H2 CDR loop. 2D1 has a 3-residue insertion in the CDR that extends the physical CDR length by 1 residue, but the other inserted residues are accommodated in the loop around H63–H64 that faces the C1 domain.

Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013
Permissions and Reprints Request Permissions
Download as Powerpoint


Generic image for table

Click to view


CDR lengths and posttranslational modifications of unusual human antibodies

Source: microbiolspec March 2014 vol. 2 no. 2 doi:10.1128/microbiolspec.AID-0012-2013

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error